Cyclacel Pharmaceuticals, Inc.
CYCC
$0.2452
-$0.0238-8.85%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 150.00% | -86.21% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 150.00% | -86.21% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 150.00% | -86.21% | |||
| SG&A Expenses | -23.88% | 1.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -40.05% | -16.79% | |||
| Operating Income | 40.26% | 16.33% | |||
| Income Before Tax | 40.94% | 14.67% | |||
| Income Tax Expenses | 49.03% | 69.57% | |||
| Earnings from Continuing Operations | 39.91% | -10.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 39.91% | -10.56% | |||
| EBIT | 40.26% | 16.33% | |||
| EBITDA | 40.25% | 16.33% | |||
| EPS Basic | 49.60% | 20.52% | |||
| Normalized Basic EPS | 50.46% | 38.66% | |||
| EPS Diluted | 49.60% | 20.52% | |||
| Normalized Diluted EPS | 50.46% | 38.66% | |||
| Average Basic Shares Outstanding | 19.22% | 39.10% | |||
| Average Diluted Shares Outstanding | 19.22% | 39.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
